Influenza vaccine (surface antigen, inactivated)
Season 2025/2026
Influvac is a vaccine for adults and children from 6 months of age. The vaccine helps protect adults and children from catching flu. The use of Influvac should be in line with official recommendations.
After vaccination with Influvac, the body's immune system (the body's natural defense system) produces its own defense (antibodies) against the disease. None of the vaccine components cause flu.
Flu is a disease that can spread quickly. It is caused by different strains of the virus, which can change every year. For this reason, vaccination of an adult or child may be necessary every year. The greatest risk of catching flu is in the cold months between October and March. If an adult or child has not been vaccinated in the autumn, it is still justified to get vaccinated until spring, as there is still a risk of catching flu. The doctor will determine the best time for vaccination.
Influvac protects adults and children against the three virus strains contained in the vaccine about 2-3 weeks after vaccination.
The incubation period of flu in the body is a few days, so if an adult or child comes into contact with the virus shortly before or shortly after vaccination, there is a possibility of catching flu.
The vaccine does not protect adults or children from catching a cold, even though some of its symptoms are similar to those of flu.
To ensure that Influvac is the right vaccine for the patient, tell your doctor, pharmacist, or nurse if any of the following apply to the adult or child who is to receive the vaccine.
If you are unsure, ask your doctor, pharmacist, or nurse to explain.
Tell your doctor if the adult or child has:
Your doctor will decide if the adult or child can be vaccinated.
If the adult or child has a disease with high fever or acute infection, vaccination should be postponed until recovery.
Fainting, feeling faint or weak, or other stress-related reactions can occur before or after any injection. If the patient has had such a reaction before, they should tell their doctor or nurse.
Tell your doctor if the adult or child is scheduled to have blood tests within a few days of vaccination against flu. In some patients, false-positive blood test results have been observed shortly after flu vaccination.
Like all vaccines, Influvac may not fully protect all vaccinated patients.
If the patient is pregnant or breastfeeding, or thinks they may be pregnant or plans to become pregnant, they should consult their doctor before receiving this vaccine.
Flu vaccines can be used at any stage of pregnancy. A larger dataset on the safety of the vaccine during pregnancy is available for the second and third trimesters compared to the first trimester, and data on flu vaccines from around the world do not indicate that the vaccine has any harmful effects during pregnancy or to the fetus.
Influvac can be used during breastfeeding.
The doctor, pharmacist, or nurse will decide whether the pregnant woman can be vaccinated with Influvac. Before taking any medicine, consult your doctor, pharmacist, or nurse.
Influvac has no or negligible influence on the ability to drive and use machines.
The vaccine contains less than 1 mmol of sodium (23 mg) per dose, which means it is "sodium-free".
The vaccine contains less than 1 mmol of potassium (39 mg) per dose, which means it is "potassium-free".
Adults receive one dose of 0.5 ml.
Children from 6 months to 17 years of age receive one dose of 0.5 ml.
Children under 9 years of age who have not been previously vaccinated or have not been fully vaccinated with a seasonal flu vaccine: a second dose of 0.5 ml should be given at least 4 weeks apart.
Children under 6 months of age: the safety and efficacy of Influvac have not been established.
The vaccine is given by a doctor or nurse intramuscularly or deep subcutaneously.
If you have any doubts about the use of the vaccine, ask your doctor, pharmacist, or nurse.
Like all medicines, Influvac can cause side effects, although not everybody gets them.
Severe allergic reactions (frequency not known, reported sporadically with Influvac)
During clinical trials with Influvac and/or the quadrivalent vaccine Influvac Tetra, the following side effects were observed. Their frequency is:
Side effect | Adults and elderly | Children | ||
18 years and older | 6 months to 17 years | 3 to 5 years | 6 to 17 years | |
Headache | Very common* | Very common | ||
Fatigue | Very common | Very common | ||
Sweating | Common | Very common | Common | Common |
Lack of appetite | Very common | Very common | ||
Nausea | Very common | |||
Abdominal pain | Very common | |||
Diarrhea | Very common | Common | Very common | |
Vomiting | Very common | Common | Very common | |
Irritability | Very common | Very common | ||
Muscle pain | Common | Very common | ||
Joint pain | Common | Common | ||
Fatigue | Very common | Very common | ||
Fever | Uncommon | Very common | Common | Common |
General feeling of being unwell | Common | Very common | ||
Shivering | Common | Common | ||
Pain at the injection site | Very common | Very common | Very common | Very common |
Redness | Common | Very common | Very common | Very common |
Swelling | Common | Common | Very common | Very common |
Bruising | Common | Common | Very common | Very common |
Hardening at the injection site | Common | Common | Common | Common |
all age groups: Frequency not known (cannot be estimated from available data) | Skin reactions that can affect the whole body, including itching, hives, or rash | |||
Vasculitis that can cause skin rash and, in very rare cases, temporary kidney problems | ||||
Nerve pain, abnormal sensations (paresthesia), febrile seizures, neurological disorders that can lead to stiffness of the neck, disorientation, numbness, pain, and weakness of the limbs, balance disorders, loss of reflexes, paralysis of part or all of the body (encephalitis and meningitis, neuritis, Guillain-Barré syndrome) |
Temporary decrease in platelet count, which can lead to increased bruising and bleeding (transient thrombocytopenia), temporary swelling of lymph nodes in the neck, armpits, or groin (transient lymphadenopathy) | |
The above side effects were observed in clinical trials with Influvac and/or the quadrivalent vaccine Influvac Tetra. | |
*Common in elderly (≥ 61 years) |
In all age groups, most of the above side effects occurred within the first 3 days of vaccination and resolved on their own within 1 to 3 days of onset. Generally, they were mild.
If you experience any side effects, including any not listed in this leaflet, please tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C
02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date stated on the carton and on the syringe after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Store the pre-filled syringe in the outer carton to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substances are:
Influenza surface antigens (hemagglutinin and neuraminidase) corresponding to the following strains*:
A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238)
15 micrograms of HA**
A/Croatia/10136RV/2023 (H3N2)-like strain (A/Croatia/10136RV/2023, X-425A)
15 micrograms of HA**
B/Austria/1359417/2021-like strain (B/Austria/1359417/2021, BVR-26)
15 micrograms of HA**
per 0.5 ml dose
* grown in chicken embryos from healthy flocks
** hemagglutinin
This vaccine is in line with the recommendations of the World Health Organization (WHO) (for the Northern Hemisphere) and EU recommendations for the 2025/2026 season.
The other ingredients of the vaccine are: potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, water for injections.
Influvac contains 0.5 ml of a clear, colorless suspension for injection in a glass pre-filled syringe with a stopper (bromobutyl rubber) with or without a needle. Each pre-filled syringe is for single use only.
Pack sizes: 1 or 10 pre-filled syringes.
Not all pack sizes may be marketed.
Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart
Dublin 15
DUBLIN
Ireland
Abbott Biologicals B.V.
Veerweg 12
8121 AA Olst, Netherlands
For more detailed information, please contact the representative of the marketing authorization holder:
Viatris Healthcare Sp. z o.o.
tel. 22 546 64 00
Austria | Influvac Tri Injektionssuspension in einer Fertigspritze, (Influenza-Impfstoff aus inaktivierten Oberflächenantigenen) |
Belgium | Influvac suspensie voor injectie in een voorgevulde spuit Griepvaccin (oppervlakte-antigenen, geïnactiveerd) |
Bulgaria | Инфлувак инжекционна суспензия в предварително напълнена спринцовка Ваксина срещу грип (повърхностен антиген, инактивиранa) |
Croatia | Influvac suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv influence (površinski antigen), inaktivirano |
Cyprus, Malta | Influvac sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated) |
Czech Republic, Denmark, Estonia, Finland, Germany, Iceland, Norway, Poland, Portugal, Slovakia, Sweden | Influvac |
France | INFLUVAC, suspension injectable en seringue préremplie vaccin grippal inactivé à antigènes de surface |
Greece | Influvac sub-unit |
Hungary | Influvac szuszpenziós injekció előretöltött fecskendőben |
Ireland | Influvac sub-unit, suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated) |
Italy | Influvac S |
Latvia | Influvac suspensija injekcijām pilnšļircē |
Lithuania | Influvac injekcinė suspensija užpildytame švirkšte |
Luxembourg | Influvac suspension injectable en seringue préremplie Vaccin contre la grippe (antigènes de surface, inactivés) |
Netherlands | Influvac, suspensie voor injectie in voorgevulde spuit 0,5 ml |
Romania | Influvac suspensie injectabilă în seringă preumplută |
Slovenia | Influvac suspenzija za injiciranje v napolnjeni injekcijski brizgi |
Spain | Influvac suspensión inyectable en jeringa precargada |
Date of last revision of the leaflet:06/2025
As with all vaccines given by injection, it should be possible to provide appropriate immediate treatment and medical care in case of an anaphylactic reaction after vaccination.
The vaccine should reach room temperature. Shake before use.
Inspect visually before administration.
Do not use the vaccine if it has changed color or if there are impurities in the suspension.
Do not mix with other medicinal products in the same syringe.
Do not administer the vaccine directly into blood vessels.
The preferred sites for intramuscular injection are the anterolateral part of the thigh (or deltoid muscle if the muscle mass is sufficient) in children from 6 months to 35 months of age, or the deltoid muscle in children from 36 months of age and in adults.
Identifiability
To improve the identifiability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.
See also section 3: How to use Influvac.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.